Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Nuvalent Inc NUVL

Healthcare Biotechnology
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:NUVL)

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

PR Newswire 3 days ago

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

PR Newswire November 12, 2024

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

PR Newswire September 18, 2024

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

PR Newswire September 16, 2024

Nuvalent Announces Public Offering of Common Stock

PR Newswire September 16, 2024

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

PR Newswire September 14, 2024

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

PR Newswire September 13, 2024

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

PR Newswire September 9, 2024

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

PR Newswire August 29, 2024
View More News ››

Opinion & Analysis (NDAQ:NUVL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NUVL)

Nuvalent Announces Publication in Cancer Discovery Detailing

Just In: $NUVL Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL...
whytestocks - September 13, 2024

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655

News; $NUVL Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to...
whytestocks - September 9, 2024

Nuvalent, Inc. (NASDAQ:NUVL): A Promising Oncology Biotech w

http://beyondspx.com/2024/08/01/nuvalent-inc-nasdaqnuvl-a-promising-oncology-biotech-with-innovative-precision-therapies/
MikeTester - August 2, 2024

eiger and nixxo

New to this board. any ideas when these two will start to work together in producing effective business in saling real products to real...
mercure - March 3, 2001

Harmony and Nixxo

eiger technology (AXA) is playing a major part in all of this. Best thing I can suggest is for those interested to go to SEDAR and print...
metmr - February 22, 2001

RE: new info on this board from CANADA EH?

Ive heard that nixxo may not be using harmony as their shell to go public. Has anyone heard similar rumours.
redln - February 10, 2001
View more Bullboard ››

Innocan Pharma Corp

Innocan Pharma Corp

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the ...
View More »